Jennifer Lachey - 15 Jul 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: KROS
Reported as of: 15 Jul 2022
Net transaction value: -$1,367,210
SEC form: 4
Accepted by SEC: 19 Jul 2022, 16:40:13 UTC
Prior SEC filing: 15 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Keith Regnante, Attorney-in-Fact

Key filing fact

Jennifer Lachey filed Form 4 for Keros Therapeutics, Inc. (KROS) on 19 Jul 2022.

Key facts

This page summarizes Jennifer Lachey's Form 4 filing for Keros Therapeutics, Inc. (KROS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Jul 2022, 16:40.

Change

Previous filing in this sequence was filed on 15 Jul 2022.
Current net transaction value: -$1,367,210.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KROS transaction

Common Stock

Options Exercise

Transaction value: $13,810
Shares: +46,034
Change %: +48%
Price: $0.3000^*
Shares after: 141,134
Date: 15 Jul 2022
Ownership: Direct

KROS transaction

Common Stock

Sale

Transaction value: $1,381,020
Shares: -46,034
Change %: -33%
Price: $30.00
Shares after: 95,100
Date: 15 Jul 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KROS transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -46,034
Change %: -84%
Price: $0.000000
Shares after: 8,755
Date: 15 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 46,034
Exercise price: $0.3000
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Footnote F2

Immediately exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .